

Declaration of Interest

- I have nothing to declare



CHART-1 Trial

Key Issues

- Primary end point
- Control group
- Autologous cells



CHART-1 Trial

Key Issues

- Primary end point
- Control group
- Autologous cells



CHART-1 Trial

Key Issues

- Primary end point
- Control group
- Autologous cells



CHART-1 Trial

Positive Features

- Robustness of preclinical grounds
- Identification of optimal candidates/delivery modalities
- Provision of a fully integrated package : cells + delivery tool



CHART-1 Trial

Positive Features

- Robustness of preclinical grounds
- Identification of optimal candidates/delivery modalities
- Provision of a fully integrated package : cells + delivery tool



CHART-1 Trial


Positive Features

- Robustness of preclinical grounds
- Identification of optimal candidates/delivery modalities
- Provision of a fully integrated package : cells + delivery tool



Cell Therapy for Heart Disease: Trial Sequential Analyses of Two Cochrane Reviews

Trial sequential analysis allows to reduce the chance of random errors due to repeat testing of accumulating data




Heart Failure (n=759)

Relative risk reduction in mortality: 35% (assuming a 15% mortality rate in controls)

Fisher et al. Clin Pharmacol Ther 2016;100:88-101.

Cell Therapy for Heart Disease: Trial Sequential Analyses of Two Cochrane Reviews

Trial sequential analysis allows to reduce the chance of random errors due to repeat testing of accumulating data



Heart Failure (n=759)

Relative risk reduction in mortality: 35% (assuming a 15% mortality rate in controls)

Fisher et al. Clin Pharmacol Ther 2016;100:88-101.